Favipiravir has a potential therapeutic effect on COVID-19. To provide support for drug research and development in China and macro decision making, this paper analyzes the patent portfolio of Favipiravir, reflects the global patent application trend, reveals the patent barriers faced by our country in the research and development of the drug. Based on the patent data and the method of patent bibliometrics, this paper shows the patent portfolio of Favipiravir from the following aspects: time distribution of patent application, technology direction of patent application year by year, country distribution of patent application year by year, technology direction of patent application in various countries, patent applicant analysis and patent licensing to China. It is found that the basic core patents of Fabiravir are controlled by Japan, the application time of related patents in China is relatively late and the manufacturing process and preparation patents in China are the main, while the application of basic compound patents is weak, which needs to be moderately strengthened.

Darunavir is the second-generation protease inhibitor for the treatment of human immunodeficiency virus (HIV) infections. In this paper, the domestic and international patent layout and the patent barriers about darunavir are studied with the Pubchem database and the Incopat database, and suggestions for the patent layout and research & development of anti-COVID-19 drugs in China are provided. It is showed that overall, the patent layout of foreign companies is more comprehensive, which has formed a higher patent barrier to the production of darunavir in China. Chinese enterprises can strengthen their patent layout in drug intermediates and drug uses to achieve local technical advantages on the basis of strengthening research ability.

Abidol is one of the candidate drugs that can be used in clinical treatment of patients with COVID-19. Based on patent data, a valuable information carrier in the field of biomedicine, this paper conducts a multi-dimensional analysis of application trends, R & D institutions, technical directions, and sorts out the general situation of domestic and foreign patent layout. This paper provides information support for drugs research and development.

This article reviewed the application of chloroquine to COVID-19 in China, and analyzed its pharmacological effects. Through retrieving the Cortellis and Incopat databases, chloroquine patents were analyzed in terms of annual application trends, applicants, indications, antiviral and anti-pulmonary diseases, etc. At last, this paper put forward some suggestions on the patent layout and research and development of chemical drugs against COVID-19 in order to provide support and inspiration for the research and development of drugs in China.

This article reviewed the pharmacological effects of hydroxychloroquine in antiviral and anti pulmonary diseases in China. Through retrieving the Cortellis and Incopat databases, hydroxychloroquine patents were analyzed in terms of annual application trends, applicants, indications, antiviral and anti-pulmonary diseases, etc. At last, this paper put forward some suggestions on the patent layout and research and development of chemical drugs against COVID-19 in order to provide support and inspiration for the research and development of drugs in China.

Ruxolitinib is one of the drugs submitted by Chinese medical workers for clinical registration. Patent is a valuable information carrier in the field of biomedicine. Based on patent data, this article reveals the current patent layout status of Ruxolitinib and the patent barriers faced by Chinese researchers in terms of application trends, R & D institutions, and technical directions. This article provides information support for drugs research and development.

Kaletra, the compound of Lopinavir and Ritonavir, has a potential therapeutic effect on COVID-19. To provide support for drug research and development in China and macro decision making, this paper analyzes the patent portfolio of Kaletra, reflects the global patent application trend, reveals the patent barriers faced by our country in the research and development of the drug. Based on the patent data and the method of patent bibliometrics, this paper shows the patent portfolio of Kaletra from the following aspects: time distribution of patent application, technology direction of patent application year by year, country distribution of patent application year by year, technology direction of patent application in various countries and patent applicant analysis. It is found that the patent portfolio of Coriolis is becoming more and more mature. In recent years, the direction of patent application mainly focuses on preparations, new uses and preparation processes. Abbvie Inc. and its parent company Abbott are the main holders of related patents. In China, the patent application mainly focuses on the preparation process and new uses of the drug, while the patent application for basic compound is weak.

The year of 2019 marks the 40th anniversary of the establishment of diplomatic relations between China and the United States. In this paper, we have searched 40 years (1979-2019) of publications, especially in the past 10 years, using "China-US Agricultural Economy" as key word from CNKI’s literature database, and network database. We adopt keyword frequency analysis methods to analyze the development of research in this field, especially to identify hot topics, high-impact research institutions and scholars, as well as high-impact studies. From the bibliometric results, it can be seen that China’s research on the field of "China-US agricultural economy" is in a stage of rapid development. This research focused on hot topics such as "China-US agricultural trade" and "agricultural policy".